J
Jong Gwang Kim
Researcher at Kyungpook National University
Publications - 157
Citations - 4551
Jong Gwang Kim is an academic researcher from Kyungpook National University. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 27, co-authored 143 publications receiving 3248 citations. Previous affiliations of Jong Gwang Kim include Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang,Narikazu Boku,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Li-Tzong Chen,Li-Tzong Chen +24 more
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Li-Tzong Chen,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Hiroki Sameshima,Yoon-Koo Kang,Narikazu Boku +24 more
TL;DR: Nivolumab treatment resulted in clinically meaningful long-term improvements in OS in patients with previously treated G/GEJ cancer in a randomized, double-blind, placebo-controlled, phase 3 trial.
Journal ArticleDOI
Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer
Jong Gwang Kim,Yee Soo Chae,Sang Kyun Sohn,Yoon Young Cho,Joon Ho Moon,Jae Yong Park,Seoung Woo Jeon,In Taek Lee,Gyu-Seog Choi,Soo-Han Jun +9 more
TL;DR: VEGF gene polymorphisms were found to be an independent prognostic marker for patients with colorectal cancer and can help identify patient subgroups at high risk of a poor disease outcome.
Journal ArticleDOI
A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
Sun Min Lim,Hyun Chang,M. J. Yoon,Y. K. Hong,Hyun-Jeong Kim,Woung Youn Chung,Cheong Soo Park,Kee-Hyun Nam,Shin Wook Kang,Min Kyoung Kim,S-W. Kim,Sang Hyub Lee,Hoon Gu Kim,I. I. Na,Yang Soo Kim,Moon Young Choi,Jong Gwang Kim,Keon Uk Park,Hwan Jung Yun,Joo Hang Kim,Byoung Chul Cho +20 more
TL;DR: Everolimus had a limited activity with low response rate in locally advanced or metastatic thyroid cancer and reasonable clinical benefit rate and safety profile may warrant further investigation.
Journal ArticleDOI
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Daniel V.T. Catenacci,Yoon-Koo Kang,Haeseong Park,Hope E. Uronis,Keun-Wook Lee,Matthew C.H. Ng,Peter C. Enzinger,Se Hoon Park,Philip J. Gold,Jill Lacy,Howard S. Hochster,Sang Cheul Oh,Yeul Hong Kim,Kristen A. Marrone,Ronan J. Kelly,Rosalyn A. Juergens,Jong Gwang Kim,Johanna C. Bendell,Thierry Alcindor,Sun Jin Sym,Eun-Kee Song,Cheng Ean Chee,Yee Chao,Sunnie Kim,A. Craig Lockhart,Keith L. Knutson,Jennifer Yen,Aleksandra Franovic,Jeffrey L. Nordstrom,Daner Li,Jon M. Wigginton,Jan K Davidson-Moncada,Minori Koshiji Rosales,Yung-Jue Bang +33 more
TL;DR: These findings serve as proof of concept of synergistic antitumour activity with the combination of an Fc-optimised anti-HER2 agent (margetuximab) along with anti-PD-1 checkpoint blockade (pembrolizumab).